KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Fulgent Genetics (FLGT) Tax Provisions (2016 - 2026)

Fulgent Genetics' Tax Provisions history spans 11 years, with the latest figure at -$700000.0 for Q1 2026.

  • On a quarterly basis, Tax Provisions fell 450.0% to -$700000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$8.2 million, a 7.52% decrease, with the full-year FY2025 number at -$7.3 million, up 10.77% from a year prior.
  • Tax Provisions hit -$700000.0 in Q1 2026 for Fulgent Genetics, up from -$4.5 million in the prior quarter.
  • Over the last five years, Tax Provisions for FLGT hit a ceiling of $48.4 million in Q1 2022 and a floor of -$22.3 million in Q4 2023.
  • Historically, Tax Provisions has averaged $920941.2 across 5 years, with a median of -$1.9 million in 2024.
  • Biggest five-year swings in Tax Provisions: soared 4803.38% in 2023 and later plummeted 450.0% in 2026.
  • Tracing FLGT's Tax Provisions over 5 years: stood at -$9.4 million in 2022, then plummeted by 137.72% to -$22.3 million in 2023, then surged by 91.69% to -$1.9 million in 2024, then plummeted by 142.05% to -$4.5 million in 2025, then skyrocketed by 84.41% to -$700000.0 in 2026.
  • Business Quant data shows Tax Provisions for FLGT at -$700000.0 in Q1 2026, -$4.5 million in Q4 2025, and -$700000.0 in Q3 2025.